Table 3. Top 10 PBS/RPBS drugs by cost to government (does not include rebates).
Drug | Cost to government | Prescriptions |
---|---|---|
1. aflibercept | $443,729,600 | 364,846 |
2. pembrolizumab | $431,701,955 | 49,694 |
3. nivolumab | $402,113,073 | 50,593 |
4. adalimumab | $297,594,138 | 274,986 |
5. denosumab | $263,487,070 | 963,893 |
6. apixaban | $248,455,067 | 3,020,507 |
7. ustekinumab | $246,990,067 | 35,554 |
8. ranibizumab | $221,730,401 | 190,316 |
9. lenalidomide | $221,365,364 | 40,554 |
10. ocrelizumab | $175,644,997 | 10,108 |